Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Virpax Pharmaceuticals ( (VRPX) ).
Virpax Pharmaceuticals has announced a $5 million public offering of common stock and pre-funded warrants, set at $0.50 per share, to support its innovative drug delivery systems targeting pain management. The funds will aid in the development of Probudur, an injectable local anesthetic technology, and other corporate purposes. Spartan Capital Securities is managing the offering, which is expected to close on November 14, 2024.
See more insights into VRPX stock on TipRanks’ Stock Analysis page.